Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia

Pediatr Blood Cancer. 2006 Aug;47(2):206-9. doi: 10.1002/pbc.20467.


The persistence of abnormal coagulation test results after standard treatment with fresh frozen plasma (FFP) poses significant problems in children with acute leukemia requiring a diagnostic lumbar puncture and intrathecal chemotherapy. We report the prophylactic use of a single dose of 90 microg/kg recombinant activated factor VII (rFVIIa) in three children and the rapid correction of abnormal coagulation test results previously not corrected by FFP. Administration of rFVIIa was useful in avoiding a delay of diagnostic lumbar punctures and intrathecal chemotherapy. Hemorrhagic complications and adverse effects of rFVIIa were not observed. Prospective evaluation of this indication and dose appears warranted. (c) 2005 Wiley-Liss, Inc.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Blood Coagulation Disorders / etiology
  • Blood Coagulation Disorders / therapy*
  • Child
  • Factor VIIa / therapeutic use*
  • Hemorrhage / prevention & control*
  • Humans
  • Infant
  • Leukemia / complications*
  • Male
  • Premedication*
  • Recombinant Proteins / therapeutic use
  • Spinal Puncture / adverse effects*


  • Recombinant Proteins
  • Factor VIIa